A. H. Belo Corp. Series A (AHC) Financials Nov 17, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
A. H. Belo Corp. Series A (AHC) Financials Nov 17, 2014, 4:23 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for A. H. Belo Corp. Series A


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 518.35M 487.31M 461.5M 440.05M 366.25M
Cost of Goods Sold (COGS) incl. D&A 530.27M 566.5M 458.43M 438.23M 359.25M
COGS excluding D&A 484.91M 528.36M 422.76M 405.52M 336.68M
Depreciation & Amortization Expense 45.36M 38.14M 35.67M 32.72M 22.57M
Depreciation 38.86M 32.9M 30.43M 27.48M 18.08M
Amortization of Intangibles 6.5M 5.24M 5.24M 5.24M 4.49M
Gross Income (11.92M) (79.19M) 3.08M 1.81M 7M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - 55.47M - 0 -
Research & Development 0 0 0 0 -
Other SG&A - 55.47M - 0 -
Other Operating Expense 0 0 0 0 0
Unusual Expense 106.39M 3.4M 8.49M 2.44M 665,000
EBIT after Unusual Expense (106.39M) (3.4M) (8.49M) (2.44M) (665,000)
Non Operating Income/Expense (677,000) 7.07M 159,000 785,000 451,000
Non-Operating Interest Income - - - 0 0
Equity in Affiliates (Pretax) 0 0 0 2.63M 2.27M
Interest Expense 1.38M 808,000 669,000 630,000 311,000
Gross Interest Expense 1.38M 808,000 669,000 630,000 311,000
Interest Capitalized 0 0 0 - 0
Pretax Income (120.37M) (131.81M) (5.92M) 2.15M 8.74M
Income Tax (12.48M) (7.58M) 5.01M 1.73M 1.58M
Income Tax - Current Domestic 1.53M 817,000 4.39M 1.22M (2.45M)
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic (14.01M) (47.88M) 839,000 514,000 4.04M
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 (39.49M) 221,000 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 (390,000) 0
Consolidated Net Income (107.9M) (124.24M) (10.93M) 29,000 7.16M
Minority Interest Expense 0 0 0 (107,000) (193,000)
Net Income (107.9M) (124.24M) (10.93M) 136,000 7.35M
Extraordinaries & Discontinued Operations 0 0 0 0 8.77M
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 8.77M
Net Income After Extraordinaries (107.9M) (124.24M) (10.93M) 136,000 16.12M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (107.9M) (124.24M) (10.93M) 136,000 7.35M
EPS (Basic) (5.25) (5.92) (0.51) 0.01 0.73
Basic Shares Outstanding 20.55M 20.99M 21.5M 21.95M 21.97M
EPS (Diluted) (5.25) (5.92) (0.51) 0.01 0.73
Diluted Shares Outstanding 20.55M 20.99M 21.5M 22.07M 22.06M
EBITDA 33.43M (96.53M) 38.74M 34.53M 29.57M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading